Isolated compounds from turmeric oil and methods of use
AssigneeCognition Therapeutics, Inc.
InventorsGilbert M. Rishton, Susan Catalano
Life of this patent
Estimating the term…
Abstract
Compounds that are central nervous system drug candidates for the treatment of cognitive decline and, more particularly, Alzheimer's disease are provided. Methods for treatment, inhibition, and/or abatement of cognitive decline and/or Alzheimer's disease with a compound or pharmaceutically acceptable salt of the invention are also provided. Also provided are methods of preparing the compounds/compositions of the invention.
Claims59
A compound comprising formula I-0
- or pharmaceutically acceptable salt thereof, wherein:
- is selected from a single bond and a double bond;
- R1 is selected from CH3, CH2, F, Cl, Br, CF3, O-alkyl, and OCF3;
- R2 is selected from CH2C(CH3)2OH and CH═C(CH3);
- and
- R3 is selected from OH and NHCH2CH(CH3)2.
(canceled)
A compound comprising formula I-1
- or pharmaceutically acceptable salt thereof, wherein:
- is selected from a single bond and a double bond;
- R1 is selected from CH3, CH2, F, Cl, Br, CF3, O-alkyl, and OCF3;
- R2 is selected from CH2C(CH3)2OH and CH═C(CH3);
- and
- R3 is selected from OH and NHCH2CH(CH3)2.
(canceled)
A compound comprising formula I-2
- or pharmaceutically acceptable salt thereof, wherein:
- is selected from a single bond and a double bond;
- R1 is selected from CH3, CH2, F, Cl, Br, CF3, O-alkyl, and OCF3;
- R2 is selected from CH2C(CH3)2OH and CH═C(CH3);
- and
- R3 is selected from OH and NHCH2CH(CH3)2.
(canceled)
A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I-0
- wherein:
- is selected from a single bond and a double bond;
- R1 is selected from CH3, CH2, F, Cl, Br, CF3, O-alkyl, and OCF3;
- R2 is selected from CH2C(CH3)2OH and CH═C(CH3) and
- R3 is selected from OH and NHCH2CH(CH3)2 or a pharmaceutically acceptable salt thereof;
- and a pharmaceutically acceptable carrier.
(canceled)
A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I-1
- wherein:
- is selected from a single bond and a double bond;
- R1 is selected from CH3, CH2, F, Cl, Br, CF3, O-alkyl, and OCF3;
- R2 is selected from CH2C(CH3)2OH and CH═C(CH3);
- and
- R3 is selected from OH and NH CH2 CH(CH3)2 or a pharmaceutically acceptable salt thereof;
- and a pharmaceutically acceptable carrier.
(canceled)
A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I-2
- wherein:
- is selected from a single bond and a double bond;
- R1 is selected from CH3, CH2, F, Cl, Br, CF3, O-alkyl, and OCF3;
- R2 is selected from CH2C(CH3)2OH and CH═C(CH3);
- and
- R3 is selected from OH and NHCH2CH(CH3)2 or a pharmaceutically acceptable salt thereof;
- and a pharmaceutically acceptable carrier.
(canceled)
A pharmaceutical composition comprising a mixture of a therapeutically effective amount of 4-(isobutylamino)-2-methyl-6-p-tolylheptan-2-ol and a therapeutically effective amount of 4-(isobutylamino)-2-methyl-6-(4-methylcyclohexa-1,3-dienyl)heptan-2-ol or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
A pharmaceutical composition comprising a mixture of a therapeutically effective amount of (6S)-4-(isobutylamino)-2-methyl-6-p-tolylheptan-2-ol and a therapeutically effective amount of (6S)-4-(isobutylamino)-2-methyl-6-(4-methylcyclohexa-1,3-dienyl)heptan-2-ol or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
(canceled)
(canceled)
(canceled)
A method for treating cognitive decline and/or Alzheimer's disease in a patient comprising administrating to the patient a therapeutically effective amount of a compound of formula I-0
- wherein:
- is selected from a single bond and a double bond;
- R1 is selected from CH3, CH2, F, Cl, Br, CF3, O-alkyl, and OCF3;
- R2 is selected from CH2C(CH3)2OH and CH═C(CH3);
- and
- R3 is selected from OH and NH CH2 CH(CH3)2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating cognitive decline and/or Alzheimer's disease in a patient comprising administrating to the patient a therapeutically effective amount of a compound of formula I-1
- wherein:
- is selected from a single bond and a double bond;
- R1 is selected from CH3, CH2, F, Cl, Br, CF3, O-alkyl, and OCF3;
- R2 is selected from CH2C(CH3)2OH and CH═C(CH3);
- and
- R3 is selected from OH and NH CH2 CH(CH3)2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating cognitive decline and/or Alzheimer's disease in a patient comprising administrating to the patient a therapeutically effective amount of a compound of formula I-2
- or pharmaceutically acceptable salt thereof, wherein:
- is selected from a single bond and a double bond;
- R1 is selected from CH3, CH2, F, Cl, Br, CF3, O-alkyl, and OCF3;
- R2 is selected from CH2C(CH3)2OH and CH═C(CH3);
- and
- R3 is selected from OH and NHCH2CH(CH3)2.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating cognitive decline and/or Alzheimer's disease in a patient comprising administrating to the patient a pharmaceutical composition comprising a mixture of a therapeutically effective amount of 4-(isobutylamino)-2-methyl-6-p-tolylheptan-2-ol and a therapeutically effective amount of 4-(isobutylamino)-2-methyl-6-(4-methylcyclohexa-1,3-dienyl)heptan-2-ol or pharmaceutically acceptable salts thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating cognitive decline and/or Alzheimer's disease in a patient comprising administrating to the patient a pharmaceutical composition comprising a mixture of a therapeutically effective amount of (6S)-4-(isobutylamino)-2-methyl-6-p-tolylheptan-2-ol and a therapeutically effective amount of (6S)-4-(isobutylamino)-2-methyl-6-(4-methylcyclohexa-1,3-dienyl)heptan-2-ol or pharmaceutically acceptable salts thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.